Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease

References

• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019 Oct;322(13):1294–1304.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514–525.
   PubMed Web of Science ®Google Scholar
• Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011 Jun;79(12):1331–1340.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011 Jul;80(1):93–104.
   PubMed Web of Science ®Google Scholar
• van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011 Jun;79(12):1341–1352.
   PubMed Web of Science ®Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May;63(5):713–735.
   PubMed Web of Science ®Google Scholar
• Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020 Jun;52(6):1193–1194. doi: 10.1007/s11255-020-02451-9
   PubMed Web of Science ®Google Scholar
• Moeinzadeh F, Raeisi V, Babahajiani M, et al. Is chronic kidney disease, a predictor of in-hospital mortality in coronavirus disease 2019 (COVID-19) patients? Adv Biomed Res. 2023;12(1):39. doi: 10.4103/abr.abr_352_21
   PubMedGoogle Scholar
• Martono FF, Mulyanti S, Mulyanti S. Risk factors associated with the severity of COVID-19. Malays J Med Sci. 2023 Jun;30(3):84–92. doi: 10.21315/mjms2023.30.3.7
   PubMed Web of Science ®Google Scholar
• Huang RC, Chiu CH, Shang HS, et al. Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center. J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):1036–1043.
   PubMedGoogle Scholar
• Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021 Oct;54(5):767–775. doi: 10.1016/j.jmii.2021.05.011
   PubMedGoogle Scholar
• Yang CJ, Wei YJ, Chang HL, et al. Remdesivir use in the coronavirus disease 2019 pandemic: a mini-review. J Microbiol Immunol Infect. 2021 Feb;54(1):27–36.
   PubMedGoogle Scholar
• Shao W, Zhang W, Fang X, et al. Challenges of SARS-CoV-2 omicron variant and appropriate countermeasures. J Microbiol Immunol Infect. 2022 Jun;55(3):387–394.
   PubMedGoogle Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509–520. doi: 10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022 Apr 14;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Cai H, Yan J, Liu S, et al. Paxlovid for hospitalized COVID-19 patients with chronic kidney disease. Antiviral Res. 2023 Aug;216:105659. doi: 10.1016/j.antiviral.2023.105659
   PubMed Web of Science ®Google Scholar
• Dufour I, Devresse A, Scohy A, et al. Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease. Kidney Res Clin Pract. 2023 Mar;42(2):275–278.
   PubMed Web of Science ®Google Scholar
• Poznański P, Augustyniak-Bartosik H, Magiera-Żak A, et al. Molnupiravir when used alone seems to Be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients. Viruses. 2022 Oct 9;14(10):2224. doi: 10.3390/v14102224
   PubMed Web of Science ®Google Scholar
• Wu JY, Liu MY, Liu TH, et al. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. J Med Virol. 2023 Jun;95(6):e28866.
   PubMed Web of Science ®Google Scholar
• Chen YC, Ho CH, Liu TH, et al. Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol. 2023 Apr;95(4):e28745.
   PubMed Web of Science ®Google Scholar
• Liu TH, Wu JY, Huang PY, et al. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19. J Med Virol. 2023 Jul;95(7):e28951.
   PubMed Web of Science ®Google Scholar
• TriNetX. Available from: https://trinetx.com/real-world-resources/publications/trinetx-publication-guidelines/
   Google Scholar
• Liu TH, Huang PY, Wu JY, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data. J Med Virol. 2023 May;95(5):e28801.
   PubMed Web of Science ®Google Scholar
• Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023 Jun;95(6):e28869.
   PubMed Web of Science ®Google Scholar
• Chang YH, Liu TH, Wu JY, et al. The association between corticosteroids and aspergillosis among COVID-19 patients. J Infect. 2023 Apr;86(4):394–396.
   PubMed Web of Science ®Google Scholar
• Chuang MH, Wu JY, Liu TH, et al. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J Med Virol. 2023 Apr;95(4):e28750.
   PubMed Web of Science ®Google Scholar
• Y-D G, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–455. doi: 10.1111/all.14657
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015 Oct 20;314(15):1637–1638. doi: 10.1001/jama.2015.13480
   PubMed Web of Science ®Google Scholar
• Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. Am Stat. 2001;55(3):182–186. doi: 10.1198/000313001317097960
   Web of Science ®Google Scholar
• Ozturk S, Turgutalp K, Arici M, et al. Characteristics and outcomes of hospitalised older patients with chronic kidney disease and COVID-19: a multicenter nationwide controlled study. Int J Clin Pract. 2021 Sep;75(9):e14428.
   PubMed Web of Science ®Google Scholar
• Ozturk S, Turgutalp K, Arici M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020 Dec 4;35(12):2083–2095. doi: 10.1093/ndt/gfaa271
   PubMed Web of Science ®Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022 Sep 5.
   Google Scholar
• National Institutes of Health. [cited 2023 Jun 28]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Major R, Selvaskandan H, Makkeyah YM, et al. The exclusion of patients with CKD in prospectively registered Interventional trials for COVID-19-a rapid review of international registry data. J Am Soc Nephrol. 2020 Oct;31(10):2250–2252.
   PubMed Web of Science ®Google Scholar
• Hiremath S, McGuinty M, Argyropoulos C, et al. Prescribing Nirmatrelvir/Ritonavir for COVID-19 in advanced CKD. Clin J Am Soc Nephrol. 2022 Aug;17(8):1247–1250.
   PubMed Web of Science ®Google Scholar
• [cited 2023 Jun 29]. Available from: https://clinicaltrials.gov/study/NCT05487040?cond=NCT05487040&rank=1
   Google Scholar
• FDA. [cited 2023 Jun 28]. Available from: https://www.fda.gov/media/155054/download
   Google Scholar
• McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022 Oct;22(10):1435–1443.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Abu-Raddad LJ, Andrews N, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022 Jun 9;40(26):3516–3527. doi: 10.1016/j.vaccine.2022.04.069
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med. 2022 May 12;386(19):1804–1816. doi: 10.1056/NEJMoa2200797
   PubMed Web of Science ®Google Scholar
• Lin KY, Wu PY, Liu WD, et al. Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. J Microbiol Immunol Infect. 2022 Jun;55(3):535–539.
   PubMedGoogle Scholar
• Navaneethan SD, Jolly SE, Schold JD, et al. Development and validation of an electronic health record-based chronic kidney disease registry. Clin J Am Soc Nephrol. 2011 Jan;6(1):40–49.
   PubMed Web of Science ®Google Scholar